Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2− advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

20261 citationsJournal Articlehybrid Open Access

Authors

Shigenori E. Nagai · Saitama Cancer Center

Masaya Hattori · Aichi Cancer Center

Tetsuhiro Yoshinami · The University of Osaka

Hiroko Masuda · Showa University

Takuho Okamura · Tokai University

Kenichi Watanabe · National Hospital Organization Hokkaido Medical Center

Takahiro Nakayama

Abstract

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

Topics & Keywords

Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Breast Cancer Treatment Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Breast Cancer

Volume 33, Issue 2, pp. 559-568

DOI: 10.1007/s12282-025-01787-3

Field-Weighted Citation Impact: 36.61